Twist Bioscience reported fiscal Q3 revenue growth of 23% year over year to $118.4 million, citing double-digit momentum across DNA synthesis, protein solutions, and NGS applications. Management said a growing customer base is using AI to design sequences as an initial antibody discovery step, and Twist forecast continued growth in that AI-driven therapeutics demand. The company also highlighted its comprehensive viral research panel, used in June to identify the Bundibugyo Ebola virus following a Democratic Republic of Congo outbreak, tying platform throughput to rapid pathogen-response use cases. Twist’s disclosure adds to evidence that synthesis and discovery infrastructure is being pulled forward by computational workflows, with customers increasingly treating AI-designed sequences as inputs into wet-lab discovery pipelines.